Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioWa has expanded the license agreement with Genentech, providing Genentech additional access to BioWa's Potelligent Technology for the research and development of select antibodies for potential therapeutic applications that require enhancement of antibody-dependent cellular cytotoxicity.
Subscribe to our email newsletter
Under the terms of the expanded license agreement, BioWa will grant to Genentech commercial rights to research, develop, manufacture and commercialize antibodies utilizing Potelligent Technology for an additional number of targets. In return, BioWa will receive milestone payments and royalties on products developed by Genentech.
Masamichi Koike, president and CEO of BioWa, said: “We feel this alliance will strongly aid in the development of more effective targeted treatments for cancer and other diseases.”